Cervical DysplasiaNCT04772937
Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia
A study testing LLETZ and LEEP in people with Cervical Dysplasia, run by Ruhr University of Bochum at 1 site in Germany.
Trial summary
Cervical dysplasia is the precursor of cervical cancer. LEEP and LLETZ are standard surgical procedures to treat cervical dysplasia. There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cervical Dysplasia
- What is being tested?
- LLETZ and LEEP
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 206 participants
- Where
- 1 siteGermany
- Study dates
- 7 Jun 2021to Nov 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed High Grade Squamous Intraepithelial Lesion (HSIL)
- Colposcopically visible lesion
- No therapy of the disease so far
Who cannot join
- Pregnancy of the patient at/after inclusion in the study; pregnancy after conization and before the control after 6 months is possible and does not lead to exclusion from the study.
- Taking immunosuppressive drugs (incl. glucocorticoids)
- Known HIV positivity
- Malignant disease requiring treatment
- Unsatisfactory colposcopy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
Dept. OBGYN Ruhr University Bochum
Herne, 44625
Clemens Tempfer, MD, +49 2323 499 ext. 1801, clemens.tempfer@marienhospital-herne.de
Clemens Tempfer, MD
About this study
Official title: Comparison of Two Surgical Approaches in the Treatment of Cervical Dysplasia: Complete Removal of the Transformation Zone (LLETZ) Versus Isolated Resection of the Colposcopically Visible Lesion (LEEP)
Cervical dysplasia is the precursor of cervical cancer. LEEP and LLETZ are standard surgical procedures to treat cervical dysplasia. There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia.
The primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).
Read the detailed description
Cervical cancer is one of the most common cancers in women and one of the leading causes of death in women worldwide. Pre-cancerous lesions (dysplasias) are detected by the preventive smear test at the gynecologist and can thus contribute to a 100% chance of cure if they are clarified by a colposcopic examination as part of the dysplasia consultation and dysplastic lesions are then surgically removed if necessary (conization).
In practice, there are four different methods by which conization can be performed: Knife Conization, Laser Conization, Large Loop Excision of the Transformation Zone (LLETZ) and Loop Electrical Excision Procedure (LEEP). The first three methods have in common that they aim to remove the entire transformation zone. The rationale for this is that both the precancerous lesions and the cervical carcinoma itself originate in the transformation zone of the cervix. This thesis would support the idea of resecting the lesion while taking the remaining healthy transformation zone along as a precaution. However, it is clear that with the removal of the entire transformation zone, healthy tissue is removed in addition to the lesion itself. Any increase in radicality may increase the complication rate of the procedure, especially with regard to the most feared long-term complication of preterm birth, because the more cervical tissue is removed, the higher the risk of subsequent preterm birth. This connection speaks in favor of the use of LEEP, in which only the visible dysplastic tissue in healthy tissue is removed in the sense of a radical resection, without at the same time also removing the entire transformation zone, especially in women who still wish to have children.
In summary, the aim of conization is on the one hand to achieve a high level of oncological safety (low recurrence rate, high R0 resection rate) by resecting sufficient dysplastic tissue, and on the other hand to avoid excessive tissue resection, because this would increase the risk of premature birth in a subsequent pregnancy.
There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. In a Pubmed literature search (search date: February 10, 2021, search terms: conization, LEEP, LLETZ, resection margin, randomized), no prospective randomized study on this topic was found. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia
The primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).
For this purpose, patients with histologically confirmed CIN II/III will be randomly assigned to one of the two surgical methods. In order to exclude an unwanted influence by unconsciously different behavior of the patients, the patient will only learn about the surgical method performed on her after the control examination 6 months postoperatively (unilateral blinding). The surgeon is not blinded for obvious technical reasons. However, in case of complications, access to the surgical report and the chosen method is possible at any time.
Immediately postoperatively, the specimen is examined histologically and evaluated with regard to the depth of the conus and the degree of dysplasia as well as the resection margins (R0= free resection margin; R1= dysplasia extends to the resection margin) by a pathology specialist.
After an interval of 6-8 months, the first follow-up examination (the so-called "test of cure") with PAP smear and HPV test is performed in accordance with the guidelines. The two groups are compared with regard to normalization of the Pap smear, HPV status and colposcopic findings (including histology in the case of colposcopic abnormalities).
For patients with negative HPV test, unremarkable cytology, histology and colposcopy, the study is terminated. These patients are considered cured and discharged to regular screening with their established gynecologist. In case of abnormalities, the further procedure is determined according to the usual clinical criteria in conformity with the guidelines: clinical control after 3 and/or 6 months or re-conization.
Secondary target criteria of the study are, in addition to the intra- and postoperative complication rate, the pain perception of the patients and the intraoperative blood loss, also the rate of negative high risk HPV tests after 6-8 months, since a negative HPV test is generally regarded as evidence of successful treatment. Thus, the negative predictive value for a negative HPV test after conization ranges from 92% to 100%. Successful therapy usually results in elimination of the HP virus. Accordingly, a negative HPV test excludes CIN persistence or recurrence with a high probability. In contrast, a persistently positive HPV test may be taken as an indication of persistence of dysplasia or as an indicator of recurrent dysplasia.
- Conditions
- Cervical Dysplasia
- Being tested
- LLETZ, LEEP
- Keywords
- cervical dysplasia, conization, surgery, cervical cancer, LLETZ, LEEP
- Medical subject headings
- Uterine Cervical Dysplasia, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LLETZProcedure or surgery
Also called Large Loop Excision of the Transformation Zone
LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
LEEPProcedure or surgery
Also called Loop Electrosurgical Excision Procedure
LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
| Study group | Role | What they receive |
|---|---|---|
| LLETZ group | Other | LLETZ (large loop excision of the transformation zone) is one of several possible surgical interventions for treating cervical dysplasia. Receives: Procedure: LLETZ |
| LEEP group | Other | LEEP (loop electrosurgical excision procedure) is one of several possible surgical interventions for treating cervical dysplasia. Receives: Procedure: LEEP |
What is being measured
The primary outcome is the main question the study is designed to answer.
Surgical specimen margin status
Oncological safety as defined by the rate of specimens with involved margins, i.e. cervical dysplasia present at the edge of the surgical specimen.
Measured: Pathology assessment of the cone specimen (within 2-4 days after surgery)
Secondary outcomes (5)
Intraoperative and postoperative complication rate
Rate of complications such as excessive bleeding, re-operation, unplanned readmission, infection
Measured: During and within 3 weeks after the procedure
Cone size
Size of the resected tissue
Measured: During surgery
Patient's pain
Pain experienced by the patients (11-item Visual Analogue Scale); minimum 0 (no pain), maximum 10 (unbearable pain)
Measured: Immediately after the surgery
HPV clearance
HPV high-risk positivity by PCR
Measured: 6 months post surgery
Cone volume
Volume of the resected tissue
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2021
- Study start7 Jun 2021
- Primary completionJun 2025 (estimated)
- Study completionNov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cervical DysplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective randomization, 1:1 allocation, group 1: LLETZ, group 2: LEEP
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 206 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ruhr University of Bochum
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Clemens Tempfer, Ruhr University of Bochum
- Investigators
- Clemens B Tempfer, MD, MBA, Principal investigator, Ruhr-Universität Bochum / Marien Hospital Herne
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04772937
- Sponsor's protocol ID
- LLETZ-2
- Status last verified
- Jan 2025
- First submitted
- 22 Feb 2021
- Last updated
- 30 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013 Dec 4;2013(12):CD001318. doi: 10.1002/14651858.CD001318.pub3.
PubMed 24302546Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol. 1997 Jul;66(1):108-13. doi: 10.1006/gyno.1997.4753.
PubMed 9234930
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Two Surgical Approaches in the Treatment of Cervical Dysplasia: Complete Removal of the Transformation Zone (LLETZ) Versus Isolated Resection of the Colposcopically Visible Lesion (LEEP)
- ClinicalTrials.gov ID
- NCT04772937
- Acronym / sponsor ID
- LLETZ-2
- Conditions
- Cervical Dysplasia
- Keywords
- cervical dysplasia, conization, surgery, cervical cancer, LLETZ, LEEP
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 206 participants (estimated)
- Lead sponsor
- Ruhr University of BochumUniversity, hospital or other
- Study start
- 7 Jun 2021 (actual)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Nov 2025 (estimated)
- First posted
- 26 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cervical dysplasia is the precursor of cervical cancer. LEEP and LLETZ are standard surgical procedures to treat cervical dysplasia. There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia.
The primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).
Detailed description
Cervical cancer is one of the most common cancers in women and one of the leading causes of death in women worldwide. Pre-cancerous lesions (dysplasias) are detected by the preventive smear test at the gynecologist and can thus contribute to a 100% chance of cure if they are clarified by a colposcopic examination as part of the dysplasia consultation and dysplastic lesions are then surgically removed if necessary (conization).
In practice, there are four different methods by which conization can be performed: Knife Conization, Laser Conization, Large Loop Excision of the Transformation Zone (LLETZ) and Loop Electrical Excision Procedure (LEEP). The first three methods have in common that they aim to remove the entire transformation zone. The rationale for this is that both the precancerous lesions and the cervical carcinoma itself originate in the transformation zone of the cervix. This thesis would support the idea of resecting the lesion while taking the remaining healthy transformation zone along as a precaution. However, it is clear that with the removal of the entire transformation zone, healthy tissue is removed in addition to the lesion itself. Any increase in radicality may increase the complication rate of the procedure, especially with regard to the most feared long-term complication of preterm birth, because the more cervical tissue is removed, the higher the risk of subsequent preterm birth. This connection speaks in favor of the use of LEEP, in which only the visible dysplastic tissue in healthy tissue is removed in the sense of a radical resection, without at the same time also removing the entire transformation zone, especially in women who still wish to have children.
In summary, the aim of conization is on the one hand to achieve a high level of oncological safety (low recurrence rate, high R0 resection rate) by resecting sufficient dysplastic tissue, and on the other hand to avoid excessive tissue resection, because this would increase the risk of premature birth in a subsequent pregnancy.
There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. In a Pubmed literature search (search date: February 10, 2021, search terms: conization, LEEP, LLETZ, resection margin, randomized), no prospective randomized study on this topic was found. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia
The primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).
For this purpose, patients with histologically confirmed CIN II/III will be randomly assigned to one of the two surgical methods. In order to exclude an unwanted influence by unconsciously different behavior of the patients, the patient will only learn about the surgical method performed on her after the control examination 6 months postoperatively (unilateral blinding). The surgeon is not blinded for obvious technical reasons. However, in case of complications, access to the surgical report and the chosen method is possible at any time.
Immediately postoperatively, the specimen is examined histologically and evaluated with regard to the depth of the conus and the degree of dysplasia as well as the resection margins (R0= free resection margin; R1= dysplasia extends to the resection margin) by a pathology specialist.
After an interval of 6-8 months, the first follow-up examination (the so-called "test of cure") with PAP smear and HPV test is performed in accordance with the guidelines. The two groups are compared with regard to normalization of the Pap smear, HPV status and colposcopic findings (including histology in the case of colposcopic abnormalities).
For patients with negative HPV test, unremarkable cytology, histology and colposcopy, the study is terminated. These patients are considered cured and discharged to regular screening with their established gynecologist. In case of abnormalities, the further procedure is determined according to the usual clinical criteria in conformity with the guidelines: clinical control after 3 and/or 6 months or re-conization.
Secondary target criteria of the study are, in addition to the intra- and postoperative complication rate, the pain perception of the patients and the intraoperative blood loss, also the rate of negative high risk HPV tests after 6-8 months, since a negative HPV test is generally regarded as evidence of successful treatment. Thus, the negative predictive value for a negative HPV test after conization ranges from 92% to 100%. Successful therapy usually results in elimination of the HP virus. Accordingly, a negative HPV test excludes CIN persistence or recurrence with a high probability. In contrast, a persistently positive HPV test may be taken as an indication of persistence of dysplasia or as an indicator of recurrent dysplasia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Prospective randomization, 1:1 allocation, group 1: LLETZ, group 2: LEEP
| Arm | Type | Receives |
|---|---|---|
| LLETZ group | Other | Procedure: LLETZLLETZ (large loop excision of the transformation zone) is one of several possible surgical interventions for treating cervical dysplasia. |
| LEEP group | Other | Procedure: LEEPLEEP (loop electrosurgical excision procedure) is one of several possible surgical interventions for treating cervical dysplasia. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Histologically confirmed High Grade Squamous Intraepithelial Lesion (HSIL)
- Colposcopically visible lesion
- No therapy of the disease so far
Key exclusion criteria (5 listed)
- Pregnancy of the patient at/after inclusion in the study; pregnancy after conization and before the control after 6 months is possible and does not lead to exclusion from the study.
- Taking immunosuppressive drugs (incl. glucocorticoids)
- Known HIV positivity
- Malignant disease requiring treatment
- Unsatisfactory colposcopy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LLETZAlso: Large Loop Excision of the Transformation ZoneLLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed | Procedure or surgery | LLETZ group |
| LEEPAlso: Loop Electrosurgical Excision ProcedureLEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone. | Procedure or surgery | LEEP group |
Primary outcome
Surgical specimen margin status
Time frame: Pathology assessment of the cone specimen (within 2-4 days after surgery)
Oncological safety as defined by the rate of specimens with involved margins, i.e. cervical dysplasia present at the edge of the surgical specimen.
5 secondary outcomes
Intraoperative and postoperative complication rate
Time frame: During and within 3 weeks after the procedure
Cone size
Time frame: During surgery
Patient's pain
Time frame: Immediately after the surgery
HPV clearance
Time frame: 6 months post surgery
Cone volume
Time frame: During surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2025.
- Background: PubMed 24302546Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013 Dec 4;2013(12):CD001318. doi: 10.1002/14651858.CD001318.pub3.
- Background: PubMed 9234930Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol. 1997 Jul;66(1):108-13. doi: 10.1006/gyno.1997.4753.
- Individual participant dataSharing planned: No
Related trials for Cervical Dysplasia
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
RecruitingObservational study
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
Cervical Cancer, Cervical Dysplasia
RecruitingObservational study
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Endometrial Cancer, Cervical Cancer
Recruiting
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
HIV (Human Immunodeficiency Virus), HPV
Recruiting
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa
HIV (Human Immunodeficiency Virus), HPV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clemens B Tempfer, MD, MBA principal investigator
Ruhr-Universität Bochum / Marien Hospital Herne
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LLETZ and LEEP in people with Cervical Dysplasia, run by Ruhr University of Bochum at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clemens B Temfper, MD, MBA (+492323499 ext. 1801, clemens.tempfer@rub.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surgical specimen margin status (time frame: Pathology assessment of the cone specimen (within 2-4 days after surgery)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04772937, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.